Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions
1 School for Mental Health and Neuroscience, Maastricht University Medical Center, Universiteitssingel 40, Maastricht, theNetherlands
2 Academic MS Center Limburg, Orbis Medical Center, Sittard, the Netherlands
3 Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, the Netherlands
4 Department of Radiology, VU University Medical Center, Amsterdam, the Netherlands
5 Postal address: Maastricht University Medical Center, Central Diagnostics Laboratory - RVE Laboratories and Imaging, Maastricht, 6202 AZ, the Netherlands
BMC Neurology 2014, 14:164 doi:10.1186/s12883-014-0164-5Published: 20 August 2014
Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on MRI as compared to either interferon beta (IFNβ) or placebo. The effect of fingolimod on MRI outcomes compared to natalizumab treatment has not been investigated in (head to head) clinical trials. Clinical experience with natalizumab is much more extended and in general practice often preferred.
This case describes a 31-year old woman with RRMS, who experienced severe side effects on natalizumab. After a voluntary four months treatment free period, a severe relapse appeared which was treated with prednisone and plasmapheresis; thereafter fingolimod was initiated. In the following months MRI signs improved spectacularly.
This case suggests that fingolimod might be a good alternative for natalizumab, especially for use in RRMS patients, with highly active, advanced disease, when natalizumab treatment is stopped due to side effects or even after a severe relapse.